ChiCTR2100053411 版本V1.3 版本创建时间2022/09/27 03:48:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053411 

最近更新日期:

Date of Last Refreshed on:

2022-09-27 03:47:54 

注册时间:

Date of Registration:

2021-11-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

一项观察宣肺止嗽合剂治疗急性支气管炎、感染后咳嗽(风邪犯肺证)有效性及安全性的随机、安慰剂对照、双盲、多中心临床研究

Public title:

A randomized, placebo-controlled, double-blind, and multi-center clinical study observing the efficacy and safety of Xuanfeizhisuheji for acute bronchitis and post-infection cough(syndrome of wind evil invading lung)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

一项观察宣肺止嗽合剂治疗急性支气管炎、感染后咳嗽(风邪犯肺证)有效性及安全性的随机、安慰剂对照、双盲、多中心临床研究

Scientific title:

A randomized, placebo-controlled, double-blind, and multi-center clinical study observing the efficacy and safety of Xuanfeizhisuheji for acute bronchitis and post-infection cough(syndrome of wind evil invading lung)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

梁伟杰 

研究负责人:

张洪春 

Applicant:

Liang Weijie 

Study leader:

Zhang Hongchun 

申请注册联系人电话:

Applicant telephone:

+86 10 83624052

研究负责人电话:

Study leader's telephone:

+86 10 84205227

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liangweijie@kangzhongshidai.com

研究负责人电子邮件:

Study leader's E-mail:

zryygcp@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市丰台区西三环南路201号

研究负责人通讯地址:

北京市朝阳区樱花园东街2号

Applicant address:

201 Third Ring Road West, Fengtai District, Beijing

Study leader's address:

2 Cherry Garden Street East, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京康众时代医学研究发展有限公司

Applicant's institution:

Beijing Kangzhong Times Medical Research and Development Co., Ltd

研究负责人所在单位:

中日友好医院

Affiliation of the Leader:

China-Japan Friendship Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

YW2021-006-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中日友好医院药物(器械)临床试验伦理委员会

Name of the ethic committee:

Ethics Committee of Drugs (Device) of China-Japan Friendship Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-09-24 00:00:00

伦理委员会联系人:

郤思远

Contact Name of the ethic committee:

Xi Siyuan

伦理委员会联系地址:

北京市朝阳区樱花园东街2号

Contact Address of the ethic committee:

2 Cherry Garden Street East, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中日友好医院

Primary sponsor:

China-Japan Friendship Hospital

研究实施负责(组长)单位地址:

北京市朝阳区樱花园东街2号

Primary sponsor's address:

2 Cherry Garden Street East, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

甘肃

市(区县):

武威

Country:

China

Province:

Gansu

City:

Wuwei

单位(医院):

甘肃普安制药股份有限公司

具体地址:

凉州区新镇路234号

Institution
hospital:

Gansu Pu'an Pharmaceutical Co., Ltd

Address:

234 Xinzhen Road, Liangzhou District

经费或物资来源:

甘肃普安制药股份有限公司

Source(s) of funding:

Gansu Pu'an Pharmaceutical Co., Ltd

Target disease:

Acute bronchitis, cough after infection (wind evil invading lung syndrome)

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价宣肺止嗽合剂治疗急性支气管炎、感染后咳嗽(风邪犯肺证)的有效性及安全性。  

Objectives of Study:

To evaluate the efficacy and safety of XuanFeiZhiSuHeJi in for acute bronchitis and Post-infection cough(wind evil invading lung syndrome).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

急性支气管炎组纳入标准:
1.西医诊断为急性支气管炎者;
2.中医辨证为风邪犯肺证者;
3.性别不限,年龄在18~75周岁(包含端点值)之间的患者;
4.自愿参与本研究且签署知情同意书者。
感染后咳嗽组纳入标准:
1.西医诊断为感染后咳嗽者;
2.中医辨证为风邪犯肺证者;
3.性别不限,年龄在18~75周岁(包含端点值)之间的患者;
4.自愿参与本研究且签署知情同意书者。

Inclusion criteria

Acute bronchitis group was included in the criteria:
1. Patients diagnosed with acute bronchitis in Western medicine;
2. Patients diagnosed with Syndrome Of Wind Evil Invading Lun in TCM;
3. Patients with no gender limitation, aged between 18 and 75 years old (including endpoint values);
4. Those who voluntarily participated in the study and signed the informed consent form.
PIC groups were included in the criteria:
1.Patients diagnosed with Post-infection cough in Western medicine;
2.Patients diagnosed with Syndrome Of Wind Evil Invading Lun in TCM;
3. Patients with no gender limitation, aged between 18 and 75 years old (including endpoint values);
4. Those who voluntarily participated in the study and signed the informed consent form.

排除标准:

急性支气管炎组排除标准:
1.患有肺癌、慢阻肺、肺结核、哮喘等慢性呼吸系统疾病者;
2.体温>38. 0℃,存在下呼吸道感染如慢性支气管炎急性加重、支气管扩张急性加重、支气管肺炎等疾病者;
3.合并心脑血管、肝、肾和造血系统严重原发性疾病的患者(血 ALT、AST超过正常值上限2倍;血肌酐超过正常值上限2倍);
4.属于过敏体质的患者;
5.妊娠期、哺乳期女性或近3个月内有生育计划者;
6.近2周内服用过与试验药物功效类似药物的患者;
7.参与本研究前3个月内接受过或正在接受其他药物临床研究者;
8.研究者认为不适合参加临床研究者(如依从性差的患者)。
感染后咳嗽组排除标准:
1.患有肺癌、慢阻肺、肺结核、哮喘等慢性呼吸系统疾病者;
2.合并心脑血管、肝、肾和造血系统严重原发性疾病的患者(血 ALT、AST超过正常值上限2倍;血肌酐超过正常值上限2倍);
3.属于过敏体质的患者;
4.妊娠期、哺乳期女性或近3个月内有生育计划者;
5.近2周内服用过与试验药物功效类似药物的患者;
6.参与本研究前3个月内接受过或正在接受其他药物临床研究者;
7.研究者认为不适合参加临床研究者(如依从性差的患者)。

Exclusion criteria:

Exclusion criteria for the acute bronchitis group:
1.Chronic respiratory diseases such as lung cancer, COPD, tuberculosis and asthma;
2.Present in patients of Body temperature> 38.0 degree, with lower respiratory tract infections such as acute aggravation of chronic bronchitis, acute aggravation of bronchiectasis, bronchopneumonia and etc.;
3. Patients with severe primary diseases of cardiovascular, liver, renal and hematopoietic system (blood ALT and AST exceed the upper limit of normal value by 2 times; blood creatinine exceeds the upper limit of normal value);
4.Patients with allergic constitution;
5.Women with pregnancy, lactation or those with family planning within the past 3 months;
6. Patients who have taken similar drugs to the test drugs in the past 2 weeks;
7. Have received or are receiving other drug clinical investigators within the 3 months prior to participating in this study;
8. The investigator is not suitable to participate in clinical investigators (such as patients with poor compliance).
Exclusion criteria for PIC group:
1.Chronic respiratory diseases such as lung cancer, COPD, tuberculosis and asthma;
2. Patients with severe primary diseases of cardiovascular, liver, renal and hematopoietic system (blood ALT and AST exceed the upper limit of normal value by 2 times; blood creatinine exceeds the upper limit of normal value);
3.Patients with allergic constitution;
4.Women with pregnancy, lactation or those with family planning within the past 3 months;
5. Patients who have taken similar drugs to the test drugs in the past 2 weeks;
6. Have received or are receiving other drug clinical investigators within the 3 months prior to participating in this study;
7. The investigator is not suitable to participate in clinical investigators (such as patients with poor compliance).

研究实施时间:

Study execute time:

From 2021-09-30 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-22 00:00:00 To 2022-10-31 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

240

Group:

test group

Sample size:

干预措施:

宣肺止咳合剂

干预措施代码:

Intervention:

Xuanfeizhisuheji

Intervention code:

组别:

对照组

样本量:

240

Group:

control group

Sample size:

干预措施:

宣肺止咳合剂模拟剂

干预措施代码:

Intervention:

Xuanfeizhisuheji placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

中日友好医院 

单位级别:

三级甲等 

Institution
hospital:

China-Japan Friendship Hospital

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京中医药大学第三附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

中国中医科学院望京医院 

单位级别:

三级甲等 

Institution
hospital:

Wangjing Hospital of CACMS

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China 

Province:

Tianjin 

City:

 

单位(医院):

天津中医药大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海中医药大学附属岳阳中西医结合医院 

单位级别:

三级甲等 

Institution
hospital:

Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China 

Province:

Hubei 

City:

Wuhan 

单位(医院):

武汉市中西医结合医院 

单位级别:

三级甲等 

Institution
hospital:

Wuhan Hospital of Integrated Traditional Chinese Medicine and Western Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China 

Province:

Jiangsu 

City:

Nanjing 

单位(医院):

江苏省中医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

吉林 

市(区县):

通化 

Country:

China 

Province:

Jilin 

City:

Tonghua 

单位(医院):

通化市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Tonghua Central Hospital

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

广西 

市(区县):

柳州 

Country:

China 

Province:

Guangxi 

City:

Liuzhou 

单位(医院):

柳州市中医医院 

单位级别:

三级甲等 

Institution
hospital:

Liuzhou Municipal Hospital of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

广西 

市(区县):

南宁 

Country:

China 

Province:

Guangxi 

City:

Nanning 

单位(医院):

广西中医药大学附属瑞康医院 

单位级别:

三级甲等 

Institution
hospital:

Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

河南 

市(区县):

郑州 

Country:

China 

Province:

Henan 

City:

Zhengzhou 

单位(医院):

郑州市中医院 

单位级别:

三级甲等 

Institution
hospital:

Zhengzhou Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

石家庄 

Country:

China 

Province:

Hebei 

City:

Shijiazhuang 

单位(医院):

河北省中医院 

单位级别:

三级甲等 

Institution
hospital:

Hebei Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

吉林 

市(区县):

白山 

Country:

China 

Province:

Jilin 

City:

Baishan 

单位(医院):

白山市中医院 

单位级别:

二级甲等 

Institution
hospital:

Baishan Hospital of Traditional Chinese Medicine

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

内蒙古 

市(区县):

呼和浩特 

Country:

China 

Province:

Inner Mongolia 

City:

Hohhot 

单位(医院):

内蒙古自治区中医医院 

单位级别:

三级甲等 

Institution
hospital:

Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

山东 

市(区县):

德州 

Country:

China 

Province:

Shandong 

City:

Dezhou 

单位(医院):

德州市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Dezhou Municipal People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

济宁 

Country:

China 

Province:

Shandong 

City:

Jining 

单位(医院):

济宁市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jining First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China 

Province:

Shandong 

City:

Jinan 

单位(医院):

山东省中医院 

单位级别:

三级甲等 

Institution
hospital:

Shandong Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广西 

市(区县):

南宁 

Country:

China 

Province:

Guangxi 

City:

Nanning 

单位(医院):

南宁市第二人民医院 

单位级别:

三级甲等 

Institution
hospital:

Nanning Second People's Hospital

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

新疆 

市(区县):

乌鲁木齐 

Country:

China 

Province:

Xinjiang 

City:

Urumqi 

单位(医院):

新疆生产建设兵团医院 

单位级别:

三级甲等 

Institution
hospital:

Xinjiang Production and Construction Corps Hospital

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

甘肃 

市(区县):

兰州 

Country:

China 

Province:

Gansu 

City:

Lanzhou 

单位(医院):

甘肃省中医院 

单位级别:

三级甲等 

Institution
hospital:

Gansu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

咳嗽缓解时间、消失时间

指标类型:

主要指标

Outcome:

Time of cough relief and disappearance

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗有效率

指标类型:

主要指标

Outcome:

response rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

莱赛斯特咳嗽生命质量问卷

指标类型:

次要指标

Outcome:

Leicester Cough Quality of Life Questionnaire

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Syndrome Score Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

咳嗽视觉模拟VAS评分

指标类型:

主要指标

Outcome:

Cough visual analogue VAS score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

liver function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

主要指标

Outcome:

renal function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体温

指标类型:

主要指标

Outcome:

(body) temperature

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

主要指标

Outcome:

blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺通气检查

指标类型:

主要指标

Outcome:

Pulmonary ventilation examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计学专业人员提供,利用SAS9.3软件模拟产生随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

Provided by statistical professionals, random numbers were simulated using SAS9.3 software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2021-11-20 19:44:44